- Home
- MAGH vs PEPG Comparison
MAGH vs PEPG Comparison
Compare MAGH & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGH
- PEPG
- Stock Information
- Founded
- MAGH 2012
- PEPG 2018
- Country
- MAGH Singapore
- PEPG United States
- Employees
- MAGH N/A
- PEPG N/A
- Industry
- MAGH Engineering & Construction
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- MAGH Industrials
- PEPG Health Care
- Exchange
- MAGH Nasdaq
- PEPG Nasdaq
- Market Cap
- MAGH 51.8M
- PEPG 45.9M
- IPO Year
- MAGH 2025
- PEPG 2022
- Fundamental
- Price
- MAGH $1.11
- PEPG $1.49
- Analyst Decision
- MAGH
- PEPG Buy
- Analyst Count
- MAGH 0
- PEPG 3
- Target Price
- MAGH N/A
- PEPG $7.67
- AVG Volume (30 Days)
- MAGH 648.0K
- PEPG 335.1K
- Earning Date
- MAGH 01-01-0001
- PEPG 11-06-2025
- Dividend Yield
- MAGH N/A
- PEPG N/A
- EPS Growth
- MAGH N/A
- PEPG N/A
- EPS
- MAGH 0.03
- PEPG N/A
- Revenue
- MAGH $13,529,576.00
- PEPG N/A
- Revenue This Year
- MAGH N/A
- PEPG N/A
- Revenue Next Year
- MAGH N/A
- PEPG N/A
- P/E Ratio
- MAGH $35.69
- PEPG N/A
- Revenue Growth
- MAGH 10.71
- PEPG N/A
- 52 Week Low
- MAGH $0.99
- PEPG $0.88
- 52 Week High
- MAGH $5.15
- PEPG $10.06
- Technical
- Relative Strength Index (RSI)
- MAGH N/A
- PEPG 64.86
- Support Level
- MAGH N/A
- PEPG $1.13
- Resistance Level
- MAGH N/A
- PEPG $1.32
- Average True Range (ATR)
- MAGH 0.00
- PEPG 0.09
- MACD
- MAGH 0.00
- PEPG 0.03
- Stochastic Oscillator
- MAGH 0.00
- PEPG 87.80
About MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.